
    
      This study was terminated on March 17th, 2006. The results of the primary analysis at the
      interim showed that the CP-316,311 group was not significantly different than the placebo on
      the primary endpoint and therefore the data monitoring committee recommended termination of
      the trial. The decision to terminate the trial was not based on any safety concerns.
    
  